Fund strategy
The purpose of the Fund is to invest in securities listed in authorized markets of companies with partial or total exposure in the health, pharmaceutical, chemical, biological and biotechnological sectors that develop products, processes or services directly or indirectly related to human fertility and genomics. Exposure to equities will range between 75% and 100%, in securities of issuers included in these economic sectors, mainly the American market, as well as the European and OECD area.
Performance
Fees and Expenses
Total Returns
Fund's details
Geographical Distribution
Fund's portfolio distribution among the different geographical areas.
| United States of America | 70,93% | |
| SWEDEN | 6,70% | |
| SWITZERLAND | 5,80% | |
| DENMARK | 3,24% | |
| CHINA | 3,12% | |
| GERMANY | 2,98% | |
| AUSTRALIA | 1,57% | |
| SPAIN | 0,47% | |
| JAPAN | 0,16% | |
| FRANCE | 0,14% |
By investments
Fund's investments distribution.
| Cooper Companies Inc Ord | 5,21% |
| Vitrolife Ab Ord | 4,80% |
| Abbvie Inc Ord | 4,68% |
| Other Assets Less Liabilities | 4,44% |
| Merck & Co Inc Ord | 4,22% |
| Thermo Fisher Scientific Inc Ord | 3,90% |
| Intellia Therapeutics Inc Ord | 3,78% |
| Perkinelmer Inc Ord | 3,47% |
| Progyny Inc Ord | 3,37% |
| Regeneron Pharmaceuticals Inc Ord | 3,30% |
By sector
Fund's possitions distribution by the sdctor they belong to.
| Healthcare | 94,82% |
| Consumer Non-cyclicals | 0,53% |
| Technology | 0,16% |
| Not Classified - Non Equity | 0,03% |
| Financials | 0,02% |
| Basic Materials | 0,01% |
| Industrials | 0,00% |
